Sygnature Discovery, a leading provider of integrated drug discovery services to pharmaceutical and biotech companies has won the award for Excellence in Science and Technology at the annual Nottingham Post Business Awards. Sygnature flew the flag for Nottingham’s growing life science industry when the team received the winner’s prize sponsored by leading law firm, Geldards. The company was selected and judged on the quality of its science, commitment to innovation and business sustainability, in the drive to discover the medicines of the future.
Archive for Sygnature Discovery
Sygnature Discovery selected as an SME Partner in €196 Million European Lead Factory, the pan-European Drug Discovery Platform
Major pharmaceutical companies, small and medium-sized enterprises (SMEs) and academia join forces in an IMI-supported Public Private Partnership (PPP) to accelerate early drug discovery and so address the ever-increasing need for innovative therapeutics to tackle unmet medical needs.
Launch of the European Lead Factory Sygnature Discovery selected as an SME Partner in €196 Million European Lead Factory
Major pharmaceutical companies, small and medium-sized enterprises (SMEs) and academia join forces in an IMI-supported Public Private Partnership (PPP) to accelerate early drug discovery and so address the ever-increasing need for innovative therapeutics to tackle unmet medical needs
Sygnature Discovery Appoints Craig Loftus as Vice-President, Business Development – North America
TweetNottingham, UK – 30th November 2012 Sygnature Discovery Limited, a leading provider of premium integrated drug discovery services to the pharmaceutical industry, today announced the appointment of Craig Loftus to the newly-created role of Vice-President, Business Development – North America. Paul Clewlow, Senior VP, Business Development stated, “I am pleased to welcome Craig Loftus [...]
BerGenBio selects Sygnature Discovery for BGB002 drug development
Bergen, October 9, 2012: BerGenBio, an emerging oncology biopharma, today announced the signing of a contract with Sygnature Discovery, Nottingham, UK, for the pre-clinical development of a small molecule inhibitor against a novel target that mediates highly aggressive drug-resistant tumours. This represents a further strengthening of the company’s pipeline with Phase I trials of lead candidate BGB324, a first-in-class AXL receptor tyrosine konase inhibitor, on track to commence within the next few months.
Sygnature Discovery Strengthens Management Team: Colin Sambrook Smith Appointed as Head of Computational Chemistry and Informatics
Nottingham, UK – 4th September 2012 – Sygnature Discovery Limited, a leading provider of integrated drug discovery services to the pharmaceutical industry, today announced the appointment of Colin Sambrook Smith to the newly-created role of Head of Computational Chemistry and Informatics.
Sygnature Discovery and Pneumolabs Establish A Strategic Alliance
Nottingham and Harrow, UK – Tuesday 15th May 2012 – Sygnature Discovery Limited, a leading provider of integrated drug discovery services to the pharmaceutical industry, and Pneumolabs (UK) Limited, a contract research company offering a range of pre-clinical research services focused on respiratory diseases, today announced they have entered into a strategic alliance. Under the terms of the agreement, Sygnature and Pneumolabs will collaborate to provide a fully-integrated drug discovery service to accelerate clients’ drug discovery programmes into development.
Sygnature Discovery Celebrates Official Opening of New Research Laboratories with a Symposium of World Class Science
Sygnature Discovery, a leading provider of integrated drug discovery services to the pharmaceutical industry, today celebrated the official opening of its new research laboratories with a symposium of world class science. Dr Stewart Adams OBE, the inventor of ibuprofen, started the festivities by officially opening the third laboratory in Sygnature’s purpose-designed and built “state-of-the-art” facility.
Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance for a Further Two Years
Sygnature Discovery Ltd., a leading provider of integrated drug discovery services to the pharmaceutical industry, and Cyprotex Discovery Ltd., the world’s largest specialist ADME-Tox/PK pre-clinical discovery and development CRO, today announced they have entered into an extension of their highly successful strategic alliance for a further 2 years.
Sygnature Discovery: New Bioscience Group Fully-Operational & Winning Projects
Sygnature Discovery, a leading provider of integrated drug discovery services to the pharmaceutical industry, has today provided an up-date on its new Bioscience group. The team was established in August 2011 and is already involved in a number of drug discovery activities for clients, including integrated discovery projects and in vitro biology-only projects.